Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H)

Allan D. Kirk, Douglas A. Hale, Roslyn B. Mannon, David E. Kleiner, Steven C. Hoffmann, Robert L. Kampen, Linda K. Cendales, Douglas K. Tadaki, David M. Harlan, John Swanson

Research output: Contribution to journalArticle

369 Scopus citations

Abstract

Background. Profound T-cell depletion before allo-transplantation with gradual posttransplant T-cell repopulation induces a state of donor-specific immune hyporesponsiveness or tolerance in some animal models. Alemtuzumab (Campath-1H, Millennium Pharmaceuticals, Cambridge, MA) is a humanized CD52-specific monoclonal antibody that produces profound T-cell depletion in humans and reduces the need for maintenance immunosuppression after renal transplantation. We therefore performed a study to determine if pretransplant T-cell depletion with alemtuzumab would induce tolerance in human renal allografts and to evaluate the nature of the alloimmune response in the setting of T-cell depletion. Methods. Seven nonsensitized recipients of living-donor kidneys were treated perioperatively with alemtuzumab and followed postoperatively without maintenance immunosuppression. Patients were evaluated clinically by peripheral flow cytometry, protocol biopsies evaluated immunohistochemically, and real-time polymerase chain reaction-based transcriptional analysis. Results. Lymphocyte depletion was profound in the periphery and secondary lymphoid tissues. All patients developed reversible rejection episodes within the first month that were characterized by predominantly monocytic (not lymphocytic) infiltrates with only rare T cells in the peripheral blood or allograft. These episodes were responsive to treatment with steroids or sirolimus or both. After therapy, patients remained rejection-free on reduced immunosuppression, generally monotherapy sirolimus, despite the recovery of lymphocytes to normal levels. Conclusions. T-cell depletion alone does not induce tolerance in humans. These data underscore a prominent role for early responding monocytes in human allograft rejection.

Original languageEnglish (US)
Pages (from-to)120-129
Number of pages10
JournalTransplantation
Volume76
Issue number1
DOIs
StatePublished - Jul 15 2003

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H)'. Together they form a unique fingerprint.

  • Cite this

    Kirk, A. D., Hale, D. A., Mannon, R. B., Kleiner, D. E., Hoffmann, S. C., Kampen, R. L., Cendales, L. K., Tadaki, D. K., Harlan, D. M., & Swanson, J. (2003). Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation, 76(1), 120-129. https://doi.org/10.1097/01.TP.0000071362.99021.D9